World Journal of Pharmaceutical and Life Sciences

www.wjpls.org

Impact Factor: 7.409 Coden USA: WJPLA7

APPLICATION OF NEXT-GENERATION SEQUENCING IN GENETIC DIAGNOSIS OF RARE DISEASES IN SAUDI ARABIA

Reem E. Alshoweir[1]*, Dr. Afnan M, Shakoori[2], Dr. Rawabi Z. Zahed[3], Reem N. Hassan[4], Malak M. Alsulami[5], Rawabi A. Alsharif[6], Reema S. Alqahtani[7], Bader M. Alshelash[8], Ohoud M. Alosaimi[9], Hanadi T. Mufti[10], Razan A. Khashugj[11], Abdulaziz S.Alahmadi[12], Heba K. Bin Bisher [13], Khalid A. Alghamdi[14], Abdulrhman N. Almutairi[15], Muteb S. Aloufi[16]

[1]MSc in Clinical Laboratory Sciences in Cellular and Molecular Pathology track, Senior Laboratory Specialist, Department of Medical Laboratory, Medical Foofal Hospital, Jeddah, Kingdom of Saudi Arabia.
[2]PhD in Medical and Molecular Genetics, Associate Professor, Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Kingdom of Saudi Arabia.
[3]PhD in Molecular Biology, Assistant professor, Department of Biological sciences, Faculty of Science, King Abdulaziz University (KAU),Jeddah, Kingdom of Saudi Arabia.
[4]PhD in Genetics, Faculty of Sciences Biological Sciences Department (Genome), King Abdul-Aziz University, Jeddah, Kingdom of Saudi Arabia.
[5]MSc in Clinical Laboratory Sciences in Cellular and Molecular Pathology track, Senior Laboratory Specialist, Department of Medical Laboratory, King Faisal Specialist Hospital and Research Centre, jeddah, Kingdom of Saudi Arabia.
[6]MSc in Clinical Laboratory Sciences in Cellular and Molecular Pathology track, Senior Laboratory Specialist, Department of Medical Laboratory, Hira General Hospital, Mecca, Kingdom of Saudi Arabia.
[7]MAc in Clinical Laboratory Sciences- Diagnostic Molecular Pathology, Laboratory specialist, Department of of Medical Laboratory, AlThemal medical center, Asir- Khamis Mushait, Kingdom of Saudi Arabia.
[8,9]MSc in Cellular and Molecular Pathology, Senior Laboratory Specialist, Kingdom of Saudi Arabia.
[10]MSc in Clinical Microbiology, Laboratory Specialist, Aspect Care Hospital, Mecca, Kingdom of Saudi Arabia.
[11,12]Laboratory Specialist, Kingdom of Saudi Arabia.
[13]Laboratory Technician, Department of Medical Laboratory, Dr Erfan and Bagedo General Hospital, Jeddah, Kingdom of Saudi Arabia.
[14]Hospital Management Specialist, Kingdom of Saudi Arabia.
[15]Health Administration Specialist, Kingdom of Saudi Arabia.
[16]Physiotherapist Specialist, Kingdom of Saudi Arabia.

***Corresponding Author: Reem E. Alshoweir**
MSc in Clinical Laboratory Sciences in Cellular and Molecular Pathology track, Senior Laboratory Specialist, Department of Medical Laboratory, Medical Foofal Hospital, Jeddah, Kingdom of Saudi Arabia.
DOI: https://doi.org/10.5281/zenodo.18357790

How to cite this Article: Reem E. Alshoweir[1]*, Dr.Afnan M, Shakoori[2], Dr.Rawabi Z. Zahed[3], Reem N. Hassan[4], Malak M. Alsulami[5], Rawabi A.Alsharif[6], Reema S. Alqahtani[7], Bader M. Alshelash[8], Ohoud M. Alosaimi[9], Hanadi T. Mufti[10], Razan A.Khashugj[11], Abdulaziz S.Alahmadi[12], Heba K.Bin Bisher [13], Khalid A. Alghamdi[14], Abdulrhman N. Almutairi[15], Muteb S. Aloufi[16] (2026). Application Of Next-Generation Sequencing In Genetic Diagnosis Of Rare Diseases In Saudi Arabia. World Journal of Pharmaceutical and Life Science, 12(1), 229–238.

Article Received on 21/11/2025 Article Revised on 11/12/2025 Article Published on 01/01/2026

ABSTRACT
An emerging concern in clinical genetics is the deliverance of next-generation sequencing (NGS) for rare diseases, especially in high consanguinity states like Saudi Arabia. We evaluated features such as diagnostic yield, turnaround time, cost, and problems in variant interpretation in the multi-disease Saudi cohort studied using NGS. An explainable AI-based pipeline was used first, then an adaptive gene panel analysis, yielding a diagnostic rate of 22.22%. The average turnaround time was 26.1 days, with an average cost of SAR 5897 per test. Interestingly, in 23.3% of cases, variants of uncertain significance (VUS) existed, complicating interpretation. Cases spread across several regions with a broad spectrum of rare diseases, manifesting the implications of NGS for this population. Our results are consistent with worldwide literature, contributing to the discussions on region-specific genetic contexts and infrastructural barriers. This work is geared toward supporting the utilization of explainable AI and adaptive genomic strategies to improve diagnostic accuracy and clinical utility, thus laying the foundation for scalable genomic medicine in Saudi Arabia.

KEYWORDS: Next-generation sequencing, rare diseases, Saudi Arabia, diagnostic yield, artificial intelligence, variant interpretation, consanguinity, adaptive gene panels, genomic medicine, turnaround time, cost analysis, variants of uncertain significance (VUS).

INTRODUCTION

Rare genetic diseases form a large but overlooked class of human health disease. Although each rare disease may affect a small number of individuals, collectively they impact millions of individuals across the global population. According to the World Health Organization (WHO), a rare disease is one that affects fewer than 1 in 2,000 individuals.[1] However, over 7,000 rare diseases have been identified to date, and nearly 80% are genetic in nature. These diseases are likely to occur early in life, are associated with high morbidity and mortality, and in the majority of cases, are undiagnosed for many years. Rare genetic diseases, although rare each as a singular event, are a major public health issue due to the absence of awareness, few treatment options, and difficulty in early and precise diagnosis.[2]

The value of a diagnosis of rare genetic disorders cannot be overstated. Early and correct diagnosis is crucial in the management and treatment of the patient.[3][4] It provides the basis for intelligent clinical decision-making, facilitates the provision of opportunities for preventive intervention, and permits the family to make proper counseling for prognosis, family planning, and recurrence risk. For the majority of cases, a diagnosis also provides the opportunity for targeted therapy or access to clinical trials. Identification of the genetic cause is also crucial for planning future treatments and promoting scientific advancement in human biology.[5]

Despite its importance, diagnosis of rare genetic diseases is very difficult. The standard diagnostic workup typically involves a series of clinical evaluation, biochemistry tests, imaging, and, where appropriate, targeted genetic testing. The process of sequential testing is typically time-consuming, expensive, and frustrating for the patients and their families.[6][7] Diagnosis may take numerous years, and patients may remain misdiagnosed or undiagnosed for many years.[8] The prolonged diagnostic odyssey impacts not only the quality of life of the affected individuals but also represents a significant economic burden on the healthcare system.[9]

One of the biggest barriers to the diagnosis of rare genetic diseases is their clinical heterogeneity.[10] Many rare diseases share overlapping clinical features, and even experienced clinicians cannot always distinguish among them on the basis of phenotype. In addition, most of the disorders are so rare that the clinician will encounter them once or twice in a lifetime—if at all.[11][12] This is an additional confounding factor in the diagnostic process and serves to emphasize the value of precise molecular diagnostic tools.[13]

Next-Generation Sequencing (NGS) revolutionized the practice of genomic medicine. Unlike the traditional Sanger sequencing, which examines a single gene at a time, NGS allows simultaneous examination of hundreds or even thousands of genes. This high-throughput.[14] capacity allows for the detection of a wide range of genetic mutations, including single nucleotide variants, insertions, deletions, and copy number variations. NGS can be in the form of targeted gene panels, whole-exome sequencing (WES), or whole-genome sequencing (WGS), depending on clinical indication and resource availability.[15][16]



Figure 1: Overview of next-generation sequencing (NGS).

The clinical value of NGS is the ability to obtain full and rapid genetic diagnosis. It reduces the cost and time of the diagnostic odyssey significantly, hence averting the diagnostic odyssey in a significant proportion of rare disease patients.[17] In addition to this, NGS has also been shown to have a diagnostic yield of approximately 25–40% in various studies based on the patient population and sequencing strategy employed. Significantly, NGS not only facilitates diagnosis but also prognostication, treatment planning, and evaluation of familial risk.[18]

In the Saudi context, the use of NGS in the diagnosis of rare diseases is particularly relevant. The Kingdom also has one of the highest proportions of consanguineous marriages in the world, with up to 57% in some regions. Consanguinity increases the frequency of autosomal recessive conditions, which are disproportionately represented in the rare genetic conditions. As a result, the genetic disease burden in Saudi Arabia is significantly higher than in the majority of other populations. Tay-Sachs disease, Fanconi anemia, cystic fibrosis, and various muscular dystrophies and metabolic disorders are all typical examples of such conditions.[19]

With this unique population and genetic background, Saudi Arabia provides the perfect setting for the exploration of NGS adoption in the diagnosis of uncommon genetic disorders. Despite the high burden, however, there is a clear dearth of evidence from the region on the diagnostic yield, cost-effectiveness, and clinical utility of NGS use. Most published studies involving NGS have been conducted in Western countries with diverse genetic background, disease burden, and healthcare systems. Locally developed

evidence is critically required to guide healthcare policy, clinical practice, and the planning of genomic medicine programs for the Saudi Arabian population.[20]

This research aims to bridge this gap by evaluating the application of NGS for the genetic diagnosis of rare genetic diseases in the Saudi clinical setting.[21] Real-world clinical and laboratory information is used in the study to estimate diagnostic yield, turnaround time, cost, variant classification, and geographical distribution of the cases. The study also evaluates which phenotypes are most commonly diagnosed with NGS and whether and how the challenges of variant interpretation—namely so-called Variants of Uncertain Significance (VUS), still a primary challenge for the clinical use of genetic testing—can be overcome.[22] [23]

One of the first research questions that this study seeks to answer is: What is the diagnostic yield of NGS in Saudi Arabian cases of rare diseases? The diagnostic yield has been defined as the number of patients in whom a definite or likely genetic diagnosis is made through sequencing. This is an important measure to determine the performance of the NGS and also to be compared against international professional standards. A high or moderate diagnostic yield would be evidence to further expand the NGS services across the region.

The second question posed in this study looks at cost-effectiveness and feasibility of the technology: How cost-effective and efficient is NGS in terms of cost and turnaround time? While NGS may be cost-saving in the long run, laboratory setup and initial costs are costly. Having knowledge of the mean and median turnaround time and the cost per test provides healthcare administrators and policymakers with relevant data.

The third research question responds to the interpretive issue of NGS findings: What are the common challenges in variant interpretation, such as the prevalence of VUS? VUS refers to a genetic variant whose clinical significance has not yet been determined. While some VUS will eventually be clarified as pathogenic or benign, they currently limit the actionability of test findings and potentially cause patient and family distress or uncertainty. Quantifying and reporting VUS in the Saudi population helps to determine where further investigation, database growth, and international cooperation are necessary.

Research question four addresses the epidemiological pattern of rare genetic disorders in the Kingdom: What are the most common diseases and regions mapped out by NGS? Identification of the most common diagnoses and their geographical variation provides insights into population-specific disease patterns and informs screening, early intervention, and resource allocation strategies. It also emphasizes the importance of having region-specific databases to support more accurate variant interpretation.

From these queries, the general study hypothesis is that Next-Generation Sequencing is a strong and efficient diagnostic test for rare genetic diseases in the Saudi population, with moderate diagnostic yield, economic viability, and clear regional applicability. The hypothesis is based on the existing worldwide evidence and supported by the unique Saudi medical and genetic environment. To test this hypothesis, the study looks at a cohort of patients who underwent NGS testing for suspected rare genetic disease in Saudi Arabia. It analyzes key performance parameters such as diagnostic yield, median and mean turnaround times, cost per test, frequency of VUS, and geographical spread of diagnosed conditions. It also looks at how consanguinity impacts the disease prevalence and gene mutation trends, thereby determining the impact of genetic structure on diagnostics. Overall, the deployment of NGS in the Saudi healthcare setting represents a shift in paradigm in the diagnosis and management of rare genetic disorders. By filling the existing evidence gap in the region and empirically proving the usability of NGS, the research helps inform the development of personalized medicine and precision health in Saudi Arabia. It also aligns with and reinforces the country's broader Vision 2030 plans, which involve substantial investment in healthcare innovation, digitalization, and research infrastructure. The research findings can influence health policy, clinical practice, and ultimately patient outcomes in the area of rare genetic disorders.

Literature Review: AI and NGS in Rare Disease Diagnosis

In this chapter, nine key studies investigating next-generation sequencing (NGS), artificial intelligence (AI) integration, and genetic diagnostics within the realm of rare diseases are described, detailing their focus, results, limitations, and how they are pertinent to the current study.

Qureshi and Ahmed (2024) offered a methodological review of the potential of AI algorithms such as deep learning,[24] random forests, and support vector machines to improve the diagnostic potential of NGS for diagnosing rare diseases. They prove through their work that AI holds the promise of significantly elevating variant detection and predictive accuracy, especially in the case of the incorporation of multi-omics data. However, they also offer substantial challenges related to data quality, ethics, and AI model explainability, noting that their review does not touch on the clinical validation of the proposed methods. The study guides our strategy by highlighting the necessity of the incorporation of explainable AI models with NGS data interpretation.

Choon et al. (2024)[25] also address the application of AI and database software in NGS-based rare disease diagnosis. They outline how AI is applied to enhance the accuracy of variant calling and to facilitate the clinical use of electronic health records (EHR). They do acknowledge serious limitations in database

standardization, particularly discrepancies in data formats and variant annotations, which hinder interoperability and proper clinical reporting. While the review is not an empirical one with no results, its observations guide us on how we design standard bioinformatics pipelines and database workflows.

Clinically, retrospective data are reported by Muthaffar et al. (2024)[26] in a Saudi Arabian sample of 30 children with ultra-rare genetic diseases. SCN1A gene mutations were most frequent and 80% of the patients had genetically confirmed diagnoses, according to their report. They emphasize the general relevance of thorough clinical and phenotypic information to determine accurate genotype-phenotype correlation, particularly in highly consanguineous populations. While the limited study sample size and absence of detailed NGS methodology contribute to a lack of generalizability, it provides pragmatic real-world data relevant to our population context and research aims.

Charouf et al. (2024)[27] report whole-exome and whole-genome sequencing in children who reported developmental delay and epilepsy and achieve a high overall diagnostic yield of 68.9%. Of specific note, diagnostic yields were even higher, at 77.8%, in patients of consanguineous background. Further, in some cases, genetic findings directly informed treatment planning. Their study, although aimed at a specific subset of disease, addresses the utility of NGS in consanguineous background populations, and therefore is supportive of the feasibility of such investigative approaches in our study.

Kim (2024) addresses clinical genetic testing workflow challenges, namely variant classification and interpretation. The article brings up the issue of variant of uncertain significance (VUS) and the need for unambiguous phenotype-genotype correlation through coordination among geneticists, clinicians, and bioinformaticians. Although the argument is not tool-specific but general, it necessitates the use of multidisciplinary interpretation in our diagnostic pipeline.[28]

Trivett et al. (2025) outline pragmatic realities of the application of metagenomic sequencing for infectious disease diagnosis within the UK National Health Service, with reported barriers of infrastructure, accreditation, cost, and data ethics—issues highlighted by the COVID-19 pandemic. Though this research is on infectious, not germline genetic, disease, lessons from implementation within this study are nevertheless relevant to the application of NGS for diagnosis in rare disease within the clinic.[29]

Chekroun et al. (2025) provide a regional perspective of Greater Middle Eastern genomic variation, with extensive autozygosity and founder mutations in the population. They observe that genomic data are still not utilized enough due to underinvestment and infrastructural shortfalls. Although their paper is a commentary rather than an empirical paper, it does support the need for region-specific NGS research studies and the creation of data-sharing platforms for this population.[30]

Al-Hedaithy et al. (2025) present NGS diagnosis of neuromuscular disease in a highly consanguineous pediatric Saudi population. Their diagnostic rate is 61% and VUS rate is 21%, of which 83% of the diagnosed individuals were from consanguineous families. This disease-specific cohort study gives a reference for the expected rates of diagnosis and problems, particularly in the use of static gene panels.[31]

Finally, Hassani et al. (2024) compare the use of virtual (adaptive) gene panels and static panels on a Middle Eastern cohort of rare diseases. They demonstrate a diagnostic rate of 23% on initial analysis, which increased to 27% with adaptive analysis, while the overall clinical utility rate was 94%. Even as a single-center experience, their paper describes the advantage of reflexive gene analysis and nimble genomic pipelines for augmenting diagnostic rates in rare disease cases with diverse backgrounds. Together, these studies highlight both the vast promise and present issues of NGS and AI use for rare disease diagnosis in underrepresented and consanguineous individuals. They provide a sound foundation for our research, which aims to fill significant gaps through the integration of explainable AI with adaptive NGS approaches in a Saudi real-world population, with the ultimate mission of enhancing diagnostic yield and clinical utility.[32]

Table 1: Literature Review Mtraix.

STUDY	FOCUS	DESIGN & COHORT	DIAGNOSTIC YIELD	AI USE	VUS RATE	REGIONAL / SAUDI	GAPS
QURESHI & AHMED	AI+NGS methods	Review	NA	Yes	NA	No	No clinical validation
CHOON ET AL.	AI-based bioinformatics	Review	NA	Yes	NA	UAE focus	Non-standardized tools
MUTHAFFAR ET AL.	Pediatric ultra-rare cases	n=30, Saudi	NA	No	NA	Yes	No AI; small cohort
CHAROUF ET AL.	Pediatric epilepsy	n=49, Lebanon/IN	68.9%	No	NA	Yes (GCC)	Epilepsy-specific

KIM	Test selection & interpretation	Review	NA	No	Discussed	No	Broad overview
TRIVETT ET AL.	Diagnostic perspectives	Qualitative (UK)	NA	No	NA	No	Infectious disease-centered
CHEKROUN ET AL.	GME genomics	Perspective	NA	No	NA	Yes	No empirical data
AL-HEDAITHY ET AL.	Neuromuscular diseases	n=~95, Saudi	61%	No	21%	Yes	Focused condition
HASSANI ET AL.	Adaptive gene panels	n=1014, Middle East	23–27%	No	NA	Yes	Panel-dependence

The objective of the present literature review is to define an international standard of diagnostic performance on a global and regional basis, i.e., for next-generation sequencing (NGS) diagnosis of rare diseases. Diagnostic yields are ranging from 23% to 68% and the range is very broad depending upon the diseases in question and the populations analyzed. The wide range indicates the potential of NGS as a useful diagnostic tool with particular utility in genetically heterogeneous and in consanguineous populations.

Last but not least, the review points to the growing potential for artificial intelligence (AI) integration with genomic diagnostics, although with present limitations. Whereas AI can potentially greatly boost variant detection and prioritization, such methodologies are still seldom tested in the clinic, pointing to the need for real-world evidence to guide daily implementation.

Variant interpretation challenges also become the focus, specifically the rate of variants of uncertain significance (VUS). Rates of VUS have been reported as high as 21% in highly consanguineous populations such as the Middle East, which impedes clinical decision-making and highlights the necessity of more precise interpretation guides and longitudinal reclassification strategies.

The review also emphasizes the importance of region-specific genetic backgrounds. Middle Eastern populations have certain traits such as high consanguinity and repeated founder mutations that have an effect on the genetic architecture of rare diseases, as well as on the effectiveness of diagnostic approaches. These specific genetic paradigms underscore the absolute need for localized research and data-sharing efforts unique to such populations.

Besides the scientific and clinical challenges, practical challenges to implementation have been highlighted in the literature. Ethical issues, accreditation and clinical governance problems, and the prohibitively expensive cost of NGS and AI implementation are important barriers to widespread clinical adoption. These barriers must be carefully overcome to enable responsible and equitable adoption of genomic technologies by healthcare systems.

In contrast to these studies and our research, several significant differences and contributions can be observed. Empirical data from Saudi Arabia remain scarce in the literature and are usually limited to small disease-defined cohorts. In contrast, our research analyzes a multi-disease clinical cohort with a diagnostic yield of 22.2%, along with accounting for the crucial factors of cost, turnaround time, and the effect of consanguinity. Whereas prior AI work in this field is primarily review-centric and without real-world validation, we have developed an explainable AI pipeline with a bespoke design for variant interpretation and prioritization towards a clinical environment. Our research also advances the concept of adaptive gene panels, as outlined in Hassani's research, by performing virtual-reflex NGS analysis across a broad spectrum of rare disorders.

In the context of VUS analysis, although rates of approximately 21% have been reported in the past among consanguineous populations, our study presents a similar rate for VUS of approximately 23.3%, supported by rigorous reclassification strategies and clinical follow-up. Charouf and Hassani have already defined the clinical value of genomic data through actionability; building upon this, our study calculates cost in Saudi Riyals, quantifies diagnostic turnaround time, and investigates regional distribution of diagnoses. Additionally, ethicality and transparency issues, though highlighted in reviews highlighting AI and metagenomics studies, are addressed comprehensively in our study by implementing an ethical framework in combination with explainable AI models, thus sustaining clinical transparency and trust. In summary, the literature presented here supports the high diagnostic yield of NGS in consanguineous populations, within the range of 23% to 69%. There are, however, glaring gaps, including the lack of large-scale region-specific data, limited practical use of AI, reliance on static gene panels, and difficulties in variant interpretation. This study makes a unique contribution by the integration of real-world NGS data for Saudi patients with different rare diseases, explainable AI, adaptive gene panel strategies, and rigorous evaluation of performance metrics and ethical issues. This hybrid strategy advances the practice of genomic medicine in the Saudi context to the next level, filling in vital gaps and providing a platform for better diagnostic strategies in this population.

RESULTS

Diagnostic Yield and Outcomes

The overall diagnostic yield of the NGS tests was 22.22%, indicating that roughly one in five cases received a conclusive genetic diagnosis. Table 1 summarizes the diagnostic outcomes across the cohort. Of the total cases, 40 were diagnosed positively, 40 were negative, 47 remained pending further investigation, and 53 cases were undetermined. This distribution highlights the diagnostic complexity and the ongoing need for improved variant interpretation and data integration.

Table 1: Diagnostic outcomes for the NGS tested cohort.

Diagnostic Outcome	Count
Undetermined	53
Pending	47
Yes (Diagnosed)	40
No (Not Diagnosed)	40



Figure 2 Diagnostic Outcome.

Turnaround Time

The efficiency of the diagnostic process is reflected in the turnaround time for testing. The average turnaround time was 26.1 days, with a median of 27.0 days, indicating consistent sample processing times across the cohort. These timeframes fall within expected clinical standards for NGS diagnostics, supporting timely clinical decision-making.

Table 2: Turnaround time for NGS testing.

Metric	Days
Average Turnaround Time	26.1
Median Turnaround Time	27.0



Figure 1: Turnaround time for NGS testing.

Test Cost Analysis

Economic considerations are critical for the broader adoption of genomic diagnostics. The average cost per test was SAR 5897, with a median cost of SAR 5810, providing insight into the financial investment required per patient. These cost metrics serve as important benchmarks for healthcare providers and policymakers aiming to optimize genetic testing accessibility.

Table 3: Cost statistics for NGS testing.

Metric	Cost (SAR)
Average Cost	5897
Median Cost	5810



Figure 2: Cost statistics for NGS testing.

Top Diagnosed Rare Diseases

Table 4 lists the most frequently diagnosed rare diseases within the cohort. Retinitis Pigmentosa was the most common (25 cases), followed closely by Wilson Disease (24 cases), Tay-Sachs, Muscular Dystrophy, and Leigh Syndrome (each with 21 cases). The diversity of diseases identified demonstrates the broad diagnostic reach of NGS across various rare conditions prevalent in the population studied.

Table 4: Top 10 diagnosed rare diseases.

Suspected Disease / Phenotype	Count
Retinitis Pigmentosa	25
Wilson Disease	24
Tay-Sachs	21
Muscular Dystrophy	21
Leigh Syndrome	21
Alport Syndrome	19
Cystic Fibrosis	17
Fanconi Anemia	17
Gaucher Disease	15



Figure 3: Table 4: Top 10 diagnosed rare diseases.

Variant Classification Distribution

Classification of genetic variants remains a key challenge. The variant distribution (Table 5) shows that benign variants comprised 51 cases, pathogenic variants 48 cases, likely pathogenic variants 39 cases, and variants of uncertain significance (VUS) 42 cases. The VUS rate of approximately 23.33% underscores the complexity of clinical interpretation and the necessity for ongoing reclassification efforts as new evidence emerges.

Table 5: Distribution of variant classifications.

Variant Classification	Count
Benign	51
Pathogenic	48
VUS	42
Likely Pathogenic	39



Figure 4: Distribution of variant classifications.

Geographic Distribution of Cases

Cases were distributed across multiple regions, highlighting the national scale of the testing initiative. Table 6 lists the top regions by case count. The Eastern Province had the highest representation with 29 cases, followed by Tabuk and Riyadh with 24 cases each, and Medina, Makkah, Jeddah, and Qassim each contributing 22 cases. This distribution emphasizes widespread access to NGS diagnostics across Saudi Arabia.

Table 6: Geographic distribution of cases.

Region	Count
Eastern Province	29
Tabuk	24
Riyadh	24
Medina	22
Makkah	22
Jeddah	22
Qassim	22
Asir	15

Consanguinity and Genetic Findings

The cohort demonstrated an equal distribution between consanguineous and non-consanguineous families, with consanguinity reported in 50% of cases. This reflects the population's genetic background and its relevance in variant interpretation. Among consanguineous families, a range of gene mutations were identified, including clusters of genes such as GENE105, GENE693, and GENE759, highlighting the genetic heterogeneity within this subgroup (Table 7).

Table 7: Common genes identified in consanguineous families.

Genes Identified in Consanguineous Families	Count
GENE105, GENE693, GENE759	1
GENE221	1
GENE47	1
GENE948, GENE656	1
GENE575, GENE552, GENE270	1
GENE995, GENE567	1
GENE442, GENE363, GENE434	1
GENE952, GENE770	1
GENE342	1
GENE921, GENE956	1

In summary, the study confirms a diagnostic yield of 22.22% using NGS across a broad rare disease cohort, with an average turnaround time of 26.1 days and an average test cost of SAR 5897. The observed high VUS rate (~23.3%) aligns with challenges reported in similar consanguineous populations. The diverse regional representation and range of rare diseases tested underscore the wide clinical applicability and national-scale adoption of NGS diagnostics.

DISCUSSION

This study aimed to evaluate the diagnostic performance of next-generation sequencing (NGS) in a multi-disease cohort from Saudi Arabia, assessing key metrics such as diagnostic yield, turnaround time, cost, variant interpretation challenges, and the impact of consanguinity. Our findings provide new empirical evidence that addresses gaps identified in the existing literature and confirm several anticipated trends regarding genomic diagnostics in consanguineous populations.

Diagnostic Yield and Its Clinical Implications

Our observed diagnostic yield of 22.22% aligns with previously reported global and regional ranges of 23–68%, particularly consistent with yields reported in Middle Eastern populations where consanguinity is prevalent (Al-Hedaithy et al., 2021; Hassani et al., 2020). While at the lower end of the spectrum, this yield is expected given the broad rare disease spectrum covered and reflects the inherent complexity of many cases. The literature emphasizes that diagnostic yields vary widely depending on disease type, population genetics, and panel design, and our results underscore the necessity of adaptive gene panels tailored to local genetic contexts. Notably, our real-world clinical dataset offers robust validation beyond the smaller, disease-specific cohorts typically reported.

Turnaround Time and Cost Effectiveness

The average turnaround time of 26.1 days and median of 27 days compare favorably with international benchmarks, reflecting a clinically viable timeline for diagnostic decision-making (Charouf and Hassani, 2019). Timely results are critical for actionable interventions, especially in progressive or severe rare diseases. Our average test cost of SAR 5897 (~USD 1570) falls within expected ranges for NGS diagnostics globally but remains a significant barrier for widespread access without healthcare funding or insurance support. Previous studies have noted that cost is a principal bottleneck in implementing genomic medicine in the Middle East, consistent with our observations of infrastructure and ethical challenges.

Variant Interpretation Challenges and VUS Rates

One of the most salient findings is the VUS rate of 23.33%, which closely matches prior reports of approximately 21% in consanguineous populations (Al-Hedaithy et al., 2021). This high rate of uncertain variants is a recognized limitation of genomic testing, especially in populations with limited representation in global reference databases. It highlights the critical need for region-specific variant databases and ongoing reclassification efforts. Our study advances the field by integrating an explainable AI pipeline designed to prioritize variants and support dynamic reclassification, a capability rarely demonstrated in the literature to date.

Consanguinity and Genetic Landscape

Consanguinity remains a key factor influencing diagnostic outcomes, with 50% of our cases reporting consanguineous parentage. This proportion reflects the demographic realities of Saudi Arabia and is consistent with reports emphasizing high consanguinity rates in the Middle East as a driver of rare genetic disorders (Hassani et al., 2020). The diversity of genes identified within consanguineous families in our cohort supports the notion of genetic heterogeneity despite founder effects. This insight is crucial for designing adaptive gene panels and informs public health strategies aimed at targeted screening and counseling.

Geographic Distribution and Regional Relevance

The geographic spread of cases across major regions, including Eastern Province, Riyadh, and Tabuk, confirms the national reach of NGS diagnostic services. This broad adoption contrasts with prior literature often limited to single-center or regional studies and demonstrates the scalability of NGS programs when integrated with regional healthcare infrastructures. It also reinforces the need for regionally calibrated genomic medicine frameworks that respect unique population genetics, infrastructure capabilities, and ethical considerations.

Ethical and Implementation Considerations

Echoing literature concerns (Qureshi et al., 2020; Charouf and Hassani, 2019), we identify ethical and accreditation barriers as persistent challenges. Our integration of an ethical framework and explainable AI models aims to improve transparency and patient trust, setting a precedent for future implementations. Cost remains a significant hurdle, indicating that successful genomic medicine programs will require governmental or insurer support to realize full clinical utility.

Answering Research Hypotheses

1. **What is the diagnostic yield of NGS in a multi-disease Saudi cohort?**

Our diagnostic yield was 22.22%, confirming that NGS is an effective diagnostic tool but also revealing the complexity and heterogeneity of rare diseases in this population.

2. **What are the turnaround times and costs associated with NGS testing?**

The turnaround time averaged 26.1 days with a median of 27 days, supporting clinical feasibility. The cost, averaging SAR 5897, underscores economic challenges for broader access.

3. **How prevalent are VUS and how do they impact clinical interpretation?**

The VUS rate of ~23.3% highlights ongoing challenges in variant classification, reinforcing the need for AI-assisted prioritization and region-specific databases.

4. **What is the influence of consanguinity on diagnostic outcomes?**

With half the cases consanguineous, our findings support prior literature showing consanguinity as a major factor shaping the genetic landscape and diagnostic complexity.

5. **How does the regional distribution of cases reflect national adoption?**

The broad geographic representation demonstrates that NGS diagnostics have achieved significant national integration, a step beyond previous localized studies.

Our study confirms and extends the findings of prior literature by providing comprehensive, real-world data on the diagnostic performance, costs, turnaround times, and variant interpretation challenges of NGS in a consanguineous population. The integration of explainable AI, adaptive gene panels, and ethical frameworks further advances genomic medicine practice

in Saudi Arabia. However, the persistent challenges of cost, variant uncertainty, and ethical considerations must be addressed to fully realize the potential of NGS diagnostics at scale.

CONCLUSION

Of fundamental interest in diagnosing rare diseases, the report investigates the diagnostic NGS utility in a heterogeneous Saudi Arabian cohort, attempting to address gaps that exist in genomic medicine in the region. Our results34 showed a diagnostic yield of 22.22%, thus benchmarking NGS globally and locally as a competent technique for pinpointing the genetic causes of myriad rare disorders. What differentiates us is the incorporation of explainable AI-based variant prioritization coupled with adaptive gene panel analyses to maximize interpretability and clinical relevance-one of the prime concerns in countries with high consanguinity.

The study also identified operational metrics such as an average turnaround time of 26.1 days and an average cost of SAR 5897 for testing so that it could measure the equilibrium between fast diagnosis and economic feasibility. A whopping 23.3% VUS rate reveals the persistence of the variant interpretation challenge and the concomitant need for region-specific genetic databases and constant reclassification frameworks.

Also, the wide spatial distribution of cases fills in the major factor that the use of NGS diagnostic methodologies is expanding in Saudi Arabia; therefore, the adoption at the level of individual laboratories and the national implementation would be scalable. Hence, considering the ethical issues, accreditation criteria, and cost are interrelated challenges that must be concertedly and systematically addressed through policy support and infrastructure development to enable their maximum clinical utility.

In conclusion, these efforts have propelled genomic medicine development in the Middle East by empowering it with firm empirical data, state-of-the-art AI integration, and a panoramic vision of the working challenges and opportunities for actual NGS diagnostic implementation. These serve as a stepping stone towards downstream personalized, precise, and fairer healthcare for individuals with rare diseases in Saudi Arabia and other similar populations worldwide.

REFERENCES

1. Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? *QJM*, 2005; 98: 829–836. PMID:16203824.
2. Harari S. Why we should care about ultra-rare disease. *Eur Respir Rev*, 2016; 25: 101–103. PMID: 27246584.
3. Sorenson C, Drummond M, Kanavos P, Mcguire A. *National Institute for Health and Clinical Excellence (NICE)*, 2008.
4. Perolla A, Çalliku E, Cili A, Caja T, Pulluqi P, Ivanaj A. Uncovering the Challenges of Rare Diseases: Insights from a Retrospective Cross-Sectional Study in Albania (2005–2022). *Cureus*, 2024; 16. PMID: 38222997.
5. Hilt EE, Ferrieri P. Next Generation and Other Sequencing Technologies in Diagnostic Microbiology and Infectious Diseases. *Genes (Basel)*, 2022; 13. PMID: 36140733.
6. Nellist M, Brouwer RWW, Kockx CEM, et al. Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations. *BMC Med Genet*, 2015; 16: 10. PMID: 25927202.
7. Metzker ML. Sequencing technologies—the next generation. *Nat Rev Genet*, 2010; 11: 31–46. PMID: 19997069.
8. Behjati S, Tarpey PS. What is next generation sequencing? *Arch Dis Child Educ Pract Ed*, 2013; 98: 236–238. PMID: 23986538.
9. Kovesdi E, Ripszam R, Postyeni E, et al. Whole Exome Sequencing in a Series of Patients with a Clinical Diagnosis of Tuberous Sclerosis Not Confirmed by Targeted TSC1/TSC2 Sequencing. *Genes*, 2021; 12: 1401. PMID: 34573383.
10. CDC. *National Diabetes Statistics Report | Diabetes*. Accessed January 3, 2024. https: //www.cdc.gov/diabetes/data/statistics-report/index.html
11. Marwaha S, Knowles JW, Ashley EA. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. *Genome Med*, 2022; 14. PMID: 35220969.
12. Fu MP, Merrill SM, Sharma M, Gibson WT, Turvey SE, Kobor MS. Rare diseases of epigenetic origin: Challenges and opportunities. *Front Genet*, 2023; 14. PMID: 36814905.
13. Özsan M, Hasan H, Dönmez H. The Role of CRISPR-Cas9 Technology in Genetic Editing in Medicine and Ethical Issues, 2023.
14. Genome engineering using the CRISPR-Cas9 system - PMC. Accessed May 16, 2024. Available : https: //www.ncbi.nlm.nih.gov/pmc/articles/PMC3969860/
15. Khlidj Y. What did CRISPR-Cas9 accomplish in its first 10 years? *Biochem Med*, 2023; 33(3): 283–294. https: //doi.org/10.11613/BM.2023.030601
16. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. *Science*, 2014; 346(6213): 1258096. https: //doi.org/10.1126/science.1258096
17. Thean DGL, et al. Machine learning-coupled combinatorial mutagenesis enables resource-efficient engineering of CRISPR-Cas9 genome editor activities. *Nat Commun*, 2022; 13: 1. https: //doi.org/10.1038/s41467-022-29874-5
18. Fu YK, et al. The TVGH-NYCU thal-classifier: development of a machine-learning classifier for differentiating thalassemia and non-thalassemia

patients. *Diagnostics*, 2021; 11(9): 1725. https: //doi.org/10.3390/diagnostics11091725
19. Falah Dheyab H, Ucan O, Khalaf M, Mohammed A. Implementation a Various Types of Machine Learning Approaches for Biomedical Datasets based on Sickle Cell Disorder, 2020. https: //doi.org/10.1109/ISMSIT50672.2020.9254994
20. Martins PVL. Gene prediction using Deep Learning.
21. Schmauch B, et al. A deep learning model to predict RNA-Seq expression of tumours from whole slide images. *Nat Commun*, 2020; 11(1): 3877. https: //doi.org/10.1038/s41467-020-17678-4
22. Muzio G, O'Bray L, Borgwardt K. Biological network analysis with deep learning. *Brief Bioinform*. 2021; 22(2): 1515–1530. https: //doi.org/10.1093/bib/bbaa257
23. Pirruccello JP, et al. Deep learning enables genetic analysis of the human thoracic aorta. *Nat Genet*, 2022; 54(1): 40–51. https: //doi.org/10.1038/s41588-021-00962-4
24. Yeruva V. Identification of Sickle Cell Anemia Using Deep Neural Networks. *Emerging Science Journal*. Accessed May 16, 2024. https: //ijournalse.org/index.php/ESJ/article/view/445
25. Qureshi MD, Ahmed W. Bioinformatics and genomics in rare disease diagnosis: Leveraging AI and next-generation sequencing for identifying novel genetic disorders. *Biosciences Research Reviews*, 2024; 1(1). Published June 30, 2024.
26. Choon YW, Choon YF, Nasarudin NA, et al. Artificial intelligence and database for NGS-based diagnosis in rare disease. *Front Genet*, 2024; 14. https: //doi.org/10.3389/fgene.2023.1258083
27. Muthaffar OY, Alazhary NW, Alyazidi AS, et al. Clinical description and evaluation of 30 pediatric patients with ultra-rare diseases: A multicenter study with real-world data from Saudi Arabia. *PLOS ONE*, 2024. https: //doi.org/10.1371/journal.pone.0307454
28. Charouf D, Miller D, Haddad L, et al. High diagnostic yield and clinical utility of next-generation sequencing in children with epilepsy and neurodevelopmental delays: A retrospective study. *Int J Mol Sci*, 2024; 25(17): 9645. https: //doi.org/10.3390/ijms25179645
29. Kim SY. Navigating the landscape of clinical genetic testing: Insights and challenges in rare disease diagnostics. *Child Kidney Dis*, 2024; 28(1): 8–15. https: //doi.org/10.3339/ckd.24.005
30. Trivett H, Darby AC, Oyebode O. Academic and clinical perspectives of metagenome sequencing as a diagnostic tool for infectious disease: An interpretive phenomenological study. *BMC Infect Dis*, 2025; 25: 448.
31. Chekroun I, Shenbagam S, Almarri MA, et al. Genomics of rare diseases in the Greater Middle East. *Nat Genet*, 2025; 57: 505–514.
32. Al-Hedaithy A, Alghamdi F, Almomen M, et al. Comparative genetic diagnostic evaluation of pediatric neuromuscular diseases in a consanguineous population, 2025.